Invisible Threat: How Airborne Pollution Fuels Antimicrobial Resistance in the EU
TSE Working Paper N. 25-1610. Job Market Paper. (Click here to see the latest version)
Abstract: Recent scientific research suggests that the environment represents an important pathway for the spread of antimicrobial resistance (AMR). This paper is the first to provide causal estimates of the impact of fine particulate matter (PM2.5) on AMR diffusion. I focus on EU countries and the period 2002 to 2019. To pin down causal effects, I use an instrumental variable approach that exploits temperature inversions as a source of exogenous shocks to air pollution. I find that a 1% increase in PM2.5 leads to about a 0.7% increase in average antibiotic resistance, but there is significant heterogeneity across pathogen-antibiotic combinations in their responsiveness to changes in pollution. I then separately estimate the direct impact of pollution on resistance, as well as the impact of an indirect channel via antibiotic consumption. When antibiotic use is accounted for, the direct influence of air pollution on AMR remains sizable and significant. Finally, I provide a counterfactual analysis assessing the impact of alternative air pollution control policies on resistance and compare their effectiveness vis- à-vis interventions aimed at reducing antibiotic use in humans. Findings imply that pollution reduction policies can be fruitfully leveraged in the fight against AMR propagation.
Outreach: Economics of antibiotics & antibioresistance journal (TSE Health Center).
COVID-19 and the role of inequality in French regional departments
with Victor Ginsburgh and Glenn Magerman. European Journal of Health Economics, 22: 311-327 (2021).
DOI: https://doi.org/10.1007/s10198-020-01254-0.
Prescription Opioids and Economic Hardship in France
with Mathias Dewatripont, Victor Ginburgh, Michel Goldman, and Patrick Legros. European Journal of Health Economics (2023).
DOI: https://doi.org/10.1007/s10198-022-01557-4.
Media coverage: LeMonde, Médor (1/2), Médor (2/2), lepharmacien.be, Alternatives Economiques, ARTE tv.
Economic Opportunity and Opioid Regulation: the Case of Codeine in France
TSE Working Paper N. 24-1563. Previous Job Market Paper. (Click here to see the latest version)
Abstract: Policies restricting access to opioid medications are often powerful tools to reduce misuse, but their effectiveness may vary depending on local socioeconomic conditions. This paper shows how economic disadvantage shapes the magnitude of responses to such policies, focusing on a 2017 French regulation that banned over-the-counter (OTC) sales of Codeine-containing drugs. I first estimate the causal impact of this regulation, using a difference in differences (DiD) approach and monthly sales data for the 94 departments of Metropolitan France. I then exploit cross-department variation in the prevalence of poverty to examine heterogeneous policy responses. I find that the policy led to a significant reduction in overall Codeine consumption, but departments in economic disadvantage experienced smaller decreases in consumption. This shows that demand-side factors can amplify or hinder the effect of supply-side interventions. I further investigate substitution patterns by using data on non-opioid analgesic use, emergency department (ED) visits, and drug-related crimes. Finally, I consider potential dynamic effects and quantify the long-term policy impact. Results imply that increased barriers to access should move in parallel with additional measures addressing the most deprived local communities to ensure that regulatory efforts do not exacerbate existing health disparities.
Marketing Intensity and Opioid Access
with Patrick Legros.
Abstract: The role played by pharmaceutical advertising in the healthcare sector is somewhat controversial. In this paper, we investigate theoretically and empirically how pharmaceutical companies adapt their advertising strategies in response to regulation, and how this, in turn, affects sales. We focus on the opioid analgesic market in France and study how pharmaceutical companies reallocate their advertising expenses across geographical areas following a law that forbids OTC Codeine sales. In our theoretical framework, advertising takes the form of a payment provided by a company's sale representative to healthcare professionals. Doctors recommend to their patients the most suitable treatment for their health status, trading off the risk of addiction and the pain relief benefits. Patients can either self-medicate or rely on a doctor's prescription. To empirically evaluate the impact of the new law, we exploit variation in marketing intensity across departments in the period preceding its application and compare before-after changes in advertising and sales for departments with low and high pre-treatment marketing exposure. We show that, following the new law, both marketing expenses and sales decrease, and this decrease is larger in departments initially characterized by more intensive marketing.
Pull Incentives, Market Size and Pharmaceutical Innovation: From Early Preclinical Research to Drug Launch
with Pierre Dubois.
COVID-19 Pandemic and Pollution: Evidence from Belgium and France
with Sofia Amaral Garcia. Learning from the curve, June 2020.
Link to publication: https://www.learningfromthecurve.net/articles/2020/06/29/covid-19-pandemic-and-pollution-evidence-from-belgium-and-france.html.